Recent Newmark Transactions
  Kaiser Cupertino MOB
  Cupertino, CA

  Total SF: 100,325
  Sales Date: 10.5.2020
  Price: $103,000,000

  Bridgewater Medical Office
  Building & Surgery Center
  Bridgewater, NJ

  Total SF: 92,915
  Sales Date: 12.11.2020
  Price: $31,320,000

  401 Southcrest Medical Office
  Building Sale
  Memphis MSA

  Total SF: 39,385
  Sales Date: 11.18.2020
  Price: Undisclosed

  Novant South Brunswick
  Medical Office Building
  Carolina Shores, NC

  Total SF: 20,000
  Sales Date: 11.30.2020
  Price: $7,285,000

  Circleville Professional Center
  Circleville, OH

  Total SF: 19,888
  Sales Date: 12.3.2020
  Price: $5,680,000

US For-Profit Hospital Industry Outlook Moved To Stable On Higher EBITDA As Patient Volumes Return To Pre-COVID Levels
Healthcare Real Estate Will Change In The Pandemic - And That's A Good Thing

The pandemic is driving healthcare providers, owners and developers to reimagine existing and future healthcare spaces. Implementing safety precautions, such as distanced furniture and touchless access points, remain a top priority for current healthcare spaces. 

November 2020 M&A Spotlight: ClearChoice Acquired
Commentary by: Eric Murphy, Managing Director

ClearChoice operates dental treatment centers across the U.S. to provide implants for chronic dental issues. ClearChoice entered into an agreement to be acquired by Aspen Dental Management via its multiple financial sponsors. The leveraged buyout is estimated at $1.1 billion.

$360M+ in MOB Transactions Closed in October 2020

Fifty-nine medical office building transactions closed in October, totaling over $360 million and 1.822 million square feet. Texas had the most medical office building transactions with nine sales (15.3% of total), followed by California with eight sales (13.6% of total). 

Executive Leadership
Todd Perman, CCIM
Vice Chairman
Medical Office Capital Markets & Investment Banking Advisors
Ben Appel
Executive Managing Director
Chris Gordon
Senior Managing Director

Michael Greeley
Senior Managing Director

Execution Team
John Cobb
Managing Director
Richard Gerakitis
Associate Director
Bryan Walsh
© 2020 Newmark
All information contained in this publication is derived from sources that are deemed to be reliable. However, Newmark Knight Frank has not verified any such information, and the same constitutes the statements and representations only of the source thereof, and not of Newmark Knight Frank. Any recipient of this publication should independently verify such information and all other information that may be material to any decision that recipient may make in response to this publication, and should consult with professionals of the recipient's choice with regard to all aspects of that decision, including its legal, financial, and tax aspects and implications. Any recipient of this publication may not, without the prior written approval of Newmark Knight Frank, distribute, disseminate, publish, transmit, copy, broadcast, upload, download, or in any other way reproduce this publication or any of the information it contains. This document is intended for informational purposes only and none of the content is intended to advise or otherwise recommend a specific strategy. It is not to be relied upon in any way to predict market movement, investment in securities, transactions, investment strategies or any other matter.